

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**TYK Medicines, Inc**  
**浙江同源康醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2410)**

**DATE OF BOARD MEETING**

The board (the “**Board**”) of directors (the “**Directors**”) of TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “**Company**”) announces that a meeting of the Board will be held on Monday, March 30, 2026 for the purpose of, among others, considering and approving the annual results of the Company and its subsidiaries for the year ended December 31, 2025 and its publication, and considering the payment of a final dividend (if any).

By Order of the Board  
**TYK Medicines, Inc**  
(浙江同源康醫藥股份有限公司)  
**Dr. WU Yusheng**

*Chairman, Executive Director and Chief Executive Officer*

Hong Kong, March 18, 2026

*As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director, Dr. LI Jun, Dr. GU Eric Hong, Dr. JIANG Mingyu, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors, and Dr. LENG Yuting, Dr. XU Wenqing, Dr. SHEN Xiuhua and Mr. JIANG Xiaolin as independent non-executive Directors.*